Literature DB >> 7703798

Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma.

X Zheng1, L Hu, F Chen, B Christensson.   

Abstract

The expression of Ki67 antigen, epidermal growth factor receptor (EGFR) and the Epstein-Barr virus (EBV)-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma (NPC) was immunohistochemically determined. In cases with sufficient material western blot analysis was applied to analyse the LMP1 expression. Biopsies from 20 Chinese and 3 Swedish patients with NPC were included in the study. Our results demonstrated a nuclear Ki67 staining, a membrane EGFR staining, and a dot-like cytoplasmic and/or membrane LMP1 staining pattern in tumour cells of NPC. The proportion of Ki67-positive cells correlated with tumour stage. A strong expression of EGFR was frequently seen in patients with tumour stages III and IV and was paralleled by a higher proportion of Ki67-positive cells. The majority of the LMP1-positive cases strongly expressed EGFR and had a higher proportion of Ki67-positive cells, indicating a possible effect of EBV LMP1 on the proliferation of tumour cells in NPC. The increased expression of EGFR and Ki67 in NPC at late tumour stage indicates their possible use in malignancy grading of NPC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7703798     DOI: 10.1016/0964-1955(94)90027-2

Source DB:  PubMed          Journal:  Eur J Cancer B Oral Oncol        ISSN: 0964-1955


  16 in total

1.  Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas.

Authors:  Yukihiro Hiraishi; Takeshi Wada; Ken Nakatani; Kenji Negoro; Shigeyuki Fujita
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

2.  Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta.

Authors:  Che-Pei Kung; David G Meckes; Nancy Raab-Traub
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

3.  Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.

Authors:  Vivian Wai Yan Lui; Cecilia Pik Yuk Lau; Kakiu Ho; Margaret Heung Ling Ng; Suk Hang Cheng; Sai-Wah Tsao; Chi Man Tsang; Kenny Ieng Kit Lei; Anthony Tc Chan; Tony Shu Kam Mok
Journal:  Invest New Drugs       Date:  2010-06-23       Impact factor: 3.850

4.  Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.

Authors:  E K Hoebe; S H Hutajulu; J van Beek; S J Stevens; D K Paramita; A E Greijer; J M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

5.  Phase I study of icotinib, an EGFR tyrosine kinase inhibitor combined with IMRT in nasopharyngeal carcinoma.

Authors:  Wei Hu; Wei Wang; Peinong Yang; Chao Zhou; Weifang Yang; Bo Wu; Hongsheng Lu; Haihua Yang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

6.  The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapy.

Authors:  Yanqin Yang; Jize Xuan; Zhiqiang Yang; Anqin Han; Ligang Xing; Jinbo Yue; Man Hu; Jinming Yu
Journal:  Med Oncol       Date:  2011-07-23       Impact factor: 3.064

7.  Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3.

Authors:  Che-Pei Kung; Nancy Raab-Traub
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

8.  The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor.

Authors:  W E Miller; H S Earp; N Raab-Traub
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Analysis of EGFR signaling pathway in nasopharyngeal carcinoma cells by quantitative phosphoproteomics.

Authors:  Lin Ruan; Xin-Hui Li; Xun-Xun Wan; Hong Yi; Cui Li; Mao-Yu Li; Peng-Fei Zhang; Gu-Qing Zeng; Jia-Quan Qu; Qiu-Yan He; Jian-Huang Li; Yu Chen; Zhu-Chu Chen; Zhi-Qiang Xiao
Journal:  Proteome Sci       Date:  2011-06-28       Impact factor: 2.480

Review 10.  Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.

Authors:  Jill Wykosky; Tim Fenton; Frank Furnari; Webster K Cavenee
Journal:  Chin J Cancer       Date:  2011-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.